Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: A cross-sectional study

Antiviral Therapy

Volumn 18, Issue 5, 2013, Pages 681-690

  Zoufaly, Alexander ^a   Fillekes, Quirine ^b   Hammerl, Raffaela ^a,c   Nassimi, Nilofar ^a,c   Jochum, Johannes ^a   Drexler, Jan F ^d   Awasom, Charles N ^e   Sunjoh, Frida ^e   Burchard, Gerd D ^a,c   Burger, David M ^b   Van Lunzen, Jan ^a   Feldt, Torsten ^c,f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e Bamenda Regional Hospital   (Cameroon)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; BLOOD SAMPLING; CAMEROON; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIARRHEA; DRUG BLOOD LEVEL; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PAPULAR RASH; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RASH; RURAL AREA; SCHOOL CHILD; SELF REPORT; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMEROON; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEDICATION ADHERENCE; PREVALENCE; QUESTIONNAIRES; RURAL POPULATION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84883234041     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2562     Document Type: Article

References (50)

1. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003;327:1019.
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.
3. American Academy of Pediatrics Committee on Pediatric AIDS, Section on International Child Health, Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 2007;119:838-845.
4. 2012 UNAIDS. UNAIDS report on the global AIDS epidemic. (Updated 20 November 2012. Accessed 29 June 2013.) Available from http://www.unaids.org/en/ media/unaids/contentassets/documents/epidemiology/2012/gr2012/ 20121120-UNAIDS-Global-Report-2012-with-annexes-en.pdf
5. WHO. Pediatric advocacy toolkit: for improved pediatric HIV diagnosis, care and treatment in high HIV prevalence countries and regions. (Updated 2011. Accessed 29 June 2013.) Available from http://whqlibdoc.who.int/hq/2011/WHO-HIV- 11.04-eng.pdf
6. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-895.
7. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296:782-793.
8. Braitstein P, Katshcke A, Shen C, et al. Retention of HIVinfected and HIV-exposed children in a comprehensive HIV clinical care programme in Western Kenya. Trop Med Int Health 2010;15:833-841.
9. KIDS-ART-LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in sub-Saharan Africa. J Acquir Immune Defic Syndr 2008;49:523-531.
10. Sutcliffe CG, Van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008;8:477-489.
11. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and amero-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 2006;20:2315-2319.
12. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr 2007;7:13.
13. Ahoua L, Guenther G, Rouzioux C, et al. Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda. BMC Pediatr 2011;11:67.
14. Vreeman RC, Wiehe SE, Pearce EC, Nyandiko WM. A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries. Pediatr Infect Dis J 2008;27:686-691.
15. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007;119:e1371-e1383.
16. Chaix ML, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. Pediatr Infect Dis J 2005;24:1072-1076.
17. Fokam J, Salpini R, Santoro MM, et al. Drug resistance among drug-I and first-line antiretroviral treatmentfailing children in Cameroon. Pediatr Infect Dis J 2011;30:1062-1068.
18. Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PloS ONE 2012;7:e36737.
19. Mullen J, Leech S, O'Shea S, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol 2002;68:299-304.
20. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. (Updated 2010. Accessed 29 June 2013.) Available from http://whqlibdoc. who.int/publications/2010/9789241599801-eng.pdf
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 12 February 2013. Accessed 29 June 2013.) Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
22. Hollanders RM, Van Ewijk-Beneken Kolmer EW, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase highperformance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000;744:65-71.
23. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003;63:741-753.
24. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003;25:393-399.
25. De Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003;42:599-605.
26. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75.
27. Van Der Leur MR, Burger DM, La Porte CJ, Koopmans PP. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIVinfected adults. Ther Drug Monit 2006;28:650-653.
28. Nettles RE. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005;293:817-829.
29. Van Dijk JH, Sutcliffe CG, Munsanje B, et al. HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy. PloS ONE 2011;6:e19006.
30. Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa-the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 2011;56:270-278.
31. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-I individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011;11:750-759.
32. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
33. Barth RE, Tempelman HA, Moraba R, Hoepelman AI. Long-term outcome of an HIV-treatment programme in rural Africa: viral suppression despite early mortality. Aids Res Treat 2011;2011:434375.
34. Chen SC, Yu JK, Harries AD, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 2008;13:513-519.
35. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PloS Med 2006;3:e356.
36. Haberer JE, Cook A, Walker AS, et al. Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PloS ONE 2011;6:e18505.
37. Fillekes Q, Mulenga V, Kabamba D, et al. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets. AIDS 2012;26:1795-1800.
38. L'homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008;22:557-565.
39. Dong BJ, Zheng Y, Hughes MD, et al. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS 2012;26:833-841.
40. Ciccacci C, Borgiani P, Ceffa S, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010;11:23-31.
41. Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007;8:86-91.
42. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an adult AIDS clinical trials group collaboration. Clin Infect Dis 2006;43:783-786.
43. González De Requena D, Núñez M, Jiménez- Nácher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002;16:290-291.
44. De Maat MM, Ter Heine R, Mulder JW, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003;59:457-462.
45. Martínez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268.
46. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PloS Med 2008;5:e109.
47. Kouanfack C, Laurent C, Peytavin G, et al. Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in ameroon. J Acquir Immune Defic Syndr 2008;48:216-219.
48. Veldkamp AI, Van Heeswijk RP, Mulder JW, et al. Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit 2001;23:606-611.
49. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012;366:2380-2389.
50. Lessells RJ, Katzenstein DK, De Oliveira T. Are subtype differences important in HIV drug resistance? Curr Opin Virol 2012;2:636-643.